To determine the outcomes of complete surgical resection of T4 prostate cancer after inductive androgen-deprivation therapy (ADT), as inductive ADT and subsequent radical prostatectomy (RP) is not recommended by any guideline yet.
Introduction
Radical prostatectomy (RP) is the preferred therapy for localised intermediate-risk prostate cancer [1] . Because a lack of evidence, treatment of high-risk prostate cancer remains controversial. Epidemiological data mainly report on androgen-deprivation therapy (ADT) alone, but recent studies also argue in favour of radiotherapy or RP in combination with ADT [2] [3] [4] [5] . The principle of an inductive ADT for highrisk prostate cancer is to downsize or even downstage the tumour before definitive treatment in order to regain operability. Taking advantage of the androgen sensitivity of hormone-naive prostate cancer, neoadjuvant ADT was hypothesised to reduce the risk of perioperative morbidity and improve long-term oncological outcome [4, 6] . The effect of pretreatment on tumour-specific mortality after consecutive RP for high-risk prostate cancer has not yet been quantified.
Only a few randomised trials have analysed neoadjuvant ADT before RP, but ADT was only used for a predetermined period without reaching the PSA nadir and excluded the patient group that most likely benefits from this approach, namely patients with locally advanced disease and therefore at high risk of oncological failure after standard treatment.
We had observed that T4 tumours reliably regress and often completely vanish clinically under inductive hormonal treatment. We furthermore had observed that the maximum tumour regression is reached at the time of PSA nadir, which is rather reliably achieved after 6-7 months of hormonal treatment. Preliminary experiences with this approach have been described by our group and others decades ago [7, 8] , but long-term data of these series have never been published. Over many years, we used this concept in order to regain operability in motivated patients who presented with obviously inoperable tumours. RP at the time of PSA nadir, either retropubic RP (RRP) or robot-assisted laparoscopic RP (RALP), turned out to be safe. Whilst regarding these operations with more palliative than curative intent, we did not pay much attention to the long-term course of these patients. However, in recent years, we realised that such patients unexpectedly and frequently can survive for >12 years. We therefore systematically analysed both the perioperative and the long-term outcome of this particular patient group.
Patients and Methods
A prospective, monocentric RP database was queried for patients with initial T4 prostate cancer, who underwent RP after inductive ADT. The primary inoperability was indicated by the finding of a fixed tumour mass at DRE, i.e. clinical stage T4. Only a few patients had MRI or CT at the time of their diagnosis. The clinical impression was corroborated by TRUS demonstrating advanced, non-organ-confined disease, by highly elevated baseline PSA levels and/or large foci of biopsy confirmed undifferentiated tumour.
ADT consisted of LHRH agonists with or without antiandrogens, which was maintained until PSA nadir was attained. All patients without a locally advanced, inoperable tumour at initial diagnosis and/or insufficient ADT were excluded from the study. After receiving ADT, patients were reexamined at their PSA nadir and underwent RP between 2000 and 2014. In addition to RP regular lymphadenectomy was performed for the right and left external iliac region (including the obturator fossa). Only for suspicious lymph nodes was an extended dissection, including the common iliac region, performed. After the introduction of the daVinci â robotic system (Intuitive Surgical Inc., Sunnyvale, CA, USA) in 2006, all patients were treated with RALP. Surgery was converted to radical cystoprostatectomy in one patient because of unexpected advanced disease with bladder infiltration. All patients were retrospectively queried from our RP database comprising 3926 patients. A comparison with a patient cohort who failed to undergo RP was therefore not possible. But to the best of our knowledge, almost all the patients who started inductive ADT with the aim of regaining operability were finally operated upon.
Operability after ADT was assessed by DRE and TRUS. Intraand postoperative complications were assessed and postoperative complications were classified according to the Clavien-Dindo classification system [9] . The secondary endpoints were oncological outcomes of overall survival (OS), prostate cancer-specific survival (PCSS), and prostate cancerspecific mortality.
Statistics
PSA response curves were designed using Sigma Plot Version 13 (Systat Software GmbH, Erkrath, Germany).
Survival outcomes were analysed with the Kaplan-Meier method and log-rank test. Statistical analysis was performed using the Statistical Package for the Social Sciences (SPSS â ) version 22.0 (SPSS Inc., IBM Corp., Armonk, NY, USA).
Results
A total of 116 patients were identified from our RP database. Figure 1 shows the inclusion and exclusion criteria for this study. At the time of diagnosis, the median (range) PSA level was 37.6 (2.44-284) ng/mL. All patients were initially classified as inoperable by the treating physician on the basis of DRE and TRUS. Inductive ADT was given for ≥3 months (median 6 months, mean 6.9 months). During ADT, the PSA level was regularly assessed. The patients were re-examined by DRE and/or TRUS after reaching their PSA nadir. Although we did not regularly screen response to ADT by MRI preoperatively, in some cases imaging revealed a drastic downsizing in the tumour extent. One example is shown and described in Figure 2 . The median (range) preoperative PSA level for all patients after inductive ADT was 0.73 (0.01-34) ng/mL (Table 1) . Only 16 patients did not comply with our recommendation to have surgery at the time of the PSA nadir for various reasons, mostly resulting in a delay of subsequent RP, when PSA levels had already started to rise again (e.g. Table 3 , patients numbers 2, 6, 9, 14, 15, 16). Figure 3 shows the PSA response curve of the cohort after initiation of inductive ADT as a percentage from each patient's baseline PSA level.
Intra-and Postoperative Complications
A total of three rectal lesions represent the main intraoperative complications. They were managed immediately by double-layer running sutures, with no need for colostomy and no further complications. Another two patients received intraoperative blood transfusions.
There were 27 postoperative complications within 90 days after RP (Table 2 ). Grade I complications included postoperative wound infection and fever without the need for antibiotics (three patients). Grade II complications included blood transfusions and insufficient vesicourethral anastomoses with prolonged catheterisation (12 patients). We recorded 12 Grade III complications, including seven percutaneous drainages for lymphocoeles and five transurethral bladder neck resections for the treatment of bladder neck stenosis. All cases with bladder neck stenosis occurred in the RRP group. There were no Grade IV or V complications.
The final pathology of the RP specimen comprised: five (4.3%) patients with pT4 tumours, whereas 75.8% of patients were down staged to pT3 and 19.8% to pT0-pT2. Positive surgical margins were described in 39.6% and tumourinvolved lymph nodes in 33.6% of the specimens (Table 2) .
Follow-up data for 111 patients were available. The median (range) follow-up time was 75 (9-167) months. The mean and median OS was 124 months (95% CI 112.8-136.6) and 156 months (95% CI 118.9-193.1), respectively (Fig. 4) . In all, 34 patients died, 20 of them of causes unrelated to prostate cancer. The estimated PCSS at 150 months was 82% (Fig. 5) . The median PCSS has not been reached to date. In all, 25 patients (22.5%) had an undetectable PSA level (<0.03 ng/mL) postoperatively, of whom 19 (76%) had not received any further therapy after a median (range) follow-up of 72 (12-159) months (Fig. 6 ). Preoperative PSA levels and pathological data of these 19 patients are shown in detail in Table 3 .
In all, 84 patients with PSA level so of >0.03 ng/mL received adjuvant therapy. A total of 32 patients (28.8%) received adjuvant or salvage radiation therapy, usually following an individual treatment concept of various urologists.
Discussion
Previous studies of neoadjuvant ADT before RP showed a substantial reduction in prostate volume, as well as a decrease in PSA level, thus lowering the positive surgical margin rate and decreasing the number of pN1 cases [10] [11] [12] . In the few a b Our present study corroborates historical data [7, 8] that described downstaging of patients with cT4 prostate cancer to clinically operable stages, which thereafter were safely treated by RP. In our present series, RP after inductive ADT was technically feasible with an overall complication rate as low as 23.2% and not exceeding Clavien-Dindo grade III within 90-days after RP. These results are comparable with data describing primarily operable prostate cancer treatment [14] . Only one patient was converted to a cystoprostatectomy because of an unexpected tumour invasion of the complete bladder trigone and both bladder pedicles. Several previous studies analysing neoadjuvant ADT in patients with high-risk, but operable prostate cancer described downstaging to pT0 in up to 6% [13, 15, 16] . We had a lower rate of complete pathological response with two patients (1.8%) only, presumably reflecting the higher tumour burden before treatment initiation. Of these two patients one developed a biochemical recurrence 6 years postoperatively. The second patient has no evidence of disease after 159 months. [16] . Furthermore, results from a single institutional trial on neoadjuvant ADT with enzalutamide included two cT4 patients that were clinically staged by MRI and underwent RP after 6 months of therapy [17] .
The OS of organ-confined high-risk prostate cancer was compared by Tewari et al. [18] for different therapeutic strategies. The median OS was 5.2 years in the conservative therapy group with ADT alone, 6.7 years in the radiation therapy group, and 9.7 years in the RP group. Our aim was to elucidate if the therapy combination of inductive ADT and subsequent RP could cure patients with cT4 tumour, initially considered as inoperable. Surprisingly, the statistical analysis resulted in a median OS of 13 years. Our present results therefore suggest longer survival than described for patients with ADT alone or with radiation therapy. Surgery for highrisk localised prostate cancer results in a biochemical recurrence rate of~45% at 5 years [19] . As most of our present patients had multimodal treatment before and after RP including ADT and radiation, biochemical endpoints could not homogeneously be applied for the whole cohort. In all, 81% of our present patients received adjuvant therapies after RP and 22.5% had an undetectable PSA level during follow-up, most of them without any adjuvant therapy, indicating long-term cancer control. Definitive cure after surgery is therefore documented for <20% of our present patient cohort (undetectable PSA without further hormonal manipulation). However, the low rate of definitive cure did not translate into a comparable rate of tumour-related deaths, which was calculated as <20% after >12 years. RP alone does therefore not seem to be curative for most of these patients, but the results suggest that resection of the primary tumour may act as a central part of a successful multimodal treatment concept for early disseminated prostate cancer.
Our present study provides some insight into the potential of cytoreductive multimodal therapy for patients with locally advanced or oligometastatic prostate cancer. It is not unlikely that more efficient drug combinations, such as chemohormonal treatment or newest generation hormonal treatment, could further improve the results when given inductively before local treatment.
An increasing number of studies suggest better survival and delay of metastatic progression for patients with prostate cancer by removing their primary tumour [20] [21] [22] . These preliminary retrospective series analysed the potential benefit of local therapy for lymph node-positive, oligometastatic and metastatic patients [5, [21] [22] [23] [24] . Whilst local treatment of the primary tumour burden seems to be associated with an OS benefit [5, 24] , an optimised treatment strategy (radiotherapy vs surgery or combination and timing of multimodal treatment) remains to be defined [25] .
Our present findings are limited by the retrospective nature of the analysis and a non-standardised ADT schedule before surgery. Another weakness of the study is the lack of information about the number of patients who failed to undergo RP after ADT, but to the best of our knowledge, non-response or even tumour progression under inductive ADT can be regarded as extremely infrequent. The inoperability of the tumour was primarily diagnosed with DRE and TRUS, whilst only a few patients had diagnostic cross-sectional imaging (Fig. 2 ).
In conclusion, our present study shows that patients with prostate cancer presenting with a fixed tumour mass can safely undergo RP after inductive ADT when PSA nadir is reached. At that time, RP becomes feasible with a low complication rate. The long-term outcome of these patients compares favourably with treatment alternatives such as ADT alone or in combination with radiotherapy. Further prospective trials should be conducted to test new treatment concepts, like chemohormonal treatment or modern hormonal concepts, as inductive schedules. Such strategies could well lead to a further prognostic improvement of locally advanced and perhaps even oligometastatic prostate cancer.
